PE20231374A1 - Variantes de anticuerpos caninos - Google Patents
Variantes de anticuerpos caninosInfo
- Publication number
- PE20231374A1 PE20231374A1 PE2023001231A PE2023001231A PE20231374A1 PE 20231374 A1 PE20231374 A1 PE 20231374A1 PE 2023001231 A PE2023001231 A PE 2023001231A PE 2023001231 A PE2023001231 A PE 2023001231A PE 20231374 A1 PE20231374 A1 PE 20231374A1
- Authority
- PE
- Peru
- Prior art keywords
- variants
- canine antibodies
- canine
- antibodies
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063084241P | 2020-09-28 | 2020-09-28 | |
| PCT/US2021/052338 WO2022067233A2 (en) | 2020-09-28 | 2021-09-28 | Canine antibody variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231374A1 true PE20231374A1 (es) | 2023-09-07 |
Family
ID=78599123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001231A PE20231374A1 (es) | 2020-09-28 | 2021-09-28 | Variantes de anticuerpos caninos |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4217384A2 (https=) |
| JP (1) | JP2023543262A (https=) |
| KR (1) | KR20230079148A (https=) |
| CN (1) | CN116438196A (https=) |
| AR (1) | AR123636A1 (https=) |
| AU (1) | AU2021349301A1 (https=) |
| BR (1) | BR112023005393A2 (https=) |
| CA (1) | CA3194936A1 (https=) |
| CL (2) | CL2023000878A1 (https=) |
| CO (1) | CO2023004102A2 (https=) |
| EC (1) | ECSP23030271A (https=) |
| IL (1) | IL301413A (https=) |
| MX (1) | MX2023003624A (https=) |
| PE (1) | PE20231374A1 (https=) |
| TW (1) | TW202229337A (https=) |
| WO (1) | WO2022067233A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115996949A (zh) * | 2020-04-17 | 2023-04-21 | 硕腾服务有限责任公司 | 犬抗体变异体 |
| KR20250026186A (ko) * | 2022-06-21 | 2025-02-25 | 조에티스 서비시즈 엘엘씨 | 갯과 항체 돌연변이체 |
| JP2026508096A (ja) | 2023-01-20 | 2026-03-10 | ゾエティス・サービシーズ・ユーケー・リミテッド | 治療抗体 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US5698762A (en) | 1994-12-09 | 1997-12-16 | Dauerman; Leonard | Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons |
| US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
| KR20070057839A (ko) | 2004-08-19 | 2007-06-07 | 제넨테크, 인크. | 변경된 이펙터 기능을 갖는 폴리펩티드 변이체 |
| DK1817340T3 (da) | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US9505829B2 (en) | 2010-08-19 | 2016-11-29 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| EP2859018B1 (en) | 2012-06-06 | 2021-09-22 | Zoetis Services LLC | Caninized anti-ngf antibodies and methods thereof |
| CN113194984A (zh) * | 2018-10-18 | 2021-07-30 | 金德雷德生物科学股份有限公司 | 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体 |
| EP3887397A1 (en) * | 2018-11-28 | 2021-10-06 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| CN113227134A (zh) * | 2018-12-05 | 2021-08-06 | 株式会社梅花治疗 | 抗体的Fc区变体 |
| US11542333B2 (en) * | 2019-01-03 | 2023-01-03 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| CN115996949A (zh) * | 2020-04-17 | 2023-04-21 | 硕腾服务有限责任公司 | 犬抗体变异体 |
-
2021
- 2021-09-28 IL IL301413A patent/IL301413A/en unknown
- 2021-09-28 KR KR1020237014355A patent/KR20230079148A/ko active Pending
- 2021-09-28 CN CN202180065886.6A patent/CN116438196A/zh active Pending
- 2021-09-28 AR ARP210102697A patent/AR123636A1/es unknown
- 2021-09-28 WO PCT/US2021/052338 patent/WO2022067233A2/en not_active Ceased
- 2021-09-28 MX MX2023003624A patent/MX2023003624A/es unknown
- 2021-09-28 BR BR112023005393A patent/BR112023005393A2/pt unknown
- 2021-09-28 AU AU2021349301A patent/AU2021349301A1/en active Pending
- 2021-09-28 JP JP2023519180A patent/JP2023543262A/ja active Pending
- 2021-09-28 EP EP21806440.0A patent/EP4217384A2/en active Pending
- 2021-09-28 TW TW110136032A patent/TW202229337A/zh unknown
- 2021-09-28 CA CA3194936A patent/CA3194936A1/en active Pending
- 2021-09-28 PE PE2023001231A patent/PE20231374A1/es unknown
-
2023
- 2023-03-27 CL CL2023000878A patent/CL2023000878A1/es unknown
- 2023-03-29 CO CONC2023/0004102A patent/CO2023004102A2/es unknown
- 2023-04-25 EC ECSENADI202330271A patent/ECSP23030271A/es unknown
-
2024
- 2024-02-29 CL CL2024000628A patent/CL2024000628A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024000628A1 (es) | 2024-07-19 |
| AU2021349301A1 (en) | 2023-08-24 |
| AR123636A1 (es) | 2022-12-28 |
| CA3194936A1 (en) | 2022-03-31 |
| US20240010716A1 (en) | 2024-01-11 |
| MX2023003624A (es) | 2023-04-11 |
| WO2022067233A3 (en) | 2022-05-27 |
| KR20230079148A (ko) | 2023-06-05 |
| ECSP23030271A (es) | 2023-07-31 |
| CL2023000878A1 (es) | 2023-10-20 |
| IL301413A (en) | 2023-05-01 |
| EP4217384A2 (en) | 2023-08-02 |
| JP2023543262A (ja) | 2023-10-13 |
| BR112023005393A2 (pt) | 2023-04-25 |
| TW202229337A (zh) | 2022-08-01 |
| CN116438196A (zh) | 2023-07-14 |
| WO2022067233A2 (en) | 2022-03-31 |
| CO2023004102A2 (es) | 2023-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003377A1 (es) | Variantes de anticuerpos caninos | |
| CL2023003376A1 (es) | Variantes de anticuerpos felinos | |
| ECSP23030271A (es) | Variantes de anticuerpos caninos | |
| PE20231640A1 (es) | Mutaciones en regiones constantes de anticuerpos felinos | |
| CL2024001562A1 (es) | Mutaciones en regiones constantes de anticuerpos caninos. | |
| UA120981C2 (uk) | Антитіло, що зв'язується з il-8, та його застосування | |
| EA201891582A1 (ru) | Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки | |
| CO2023007146A2 (es) | Variantes de anticuerpos bovinos | |
| TR201901841T4 (tr) | Her antikorlarının sabit dozlaması. | |
| SA523450918B1 (ar) | أجسام مضادة للنكتين-4 واستخداماتها | |
| EA201992776A1 (ru) | Белки на основе антитела с привитым цитокином и способы их применения при иммунных нарушениях | |
| ECSP23030307A (es) | Variantes de anticuerpos felinos | |
| PE20230259A1 (es) | Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso | |
| CR20240255A (es) | Anticuerpo anti-trems y usos del mismo | |
| MX2025002524A (es) | Mutantes de anticuerpos equinos | |
| EA202192998A1 (ru) | CLEC12a-СВЯЗЫВАЮЩИЕ ПОЛИПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ | |
| EA201991614A1 (ru) | СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ |